Notice Received - could this be it?, page-36

Name changed from Eco Quest in November 2013. Another stem cell company looking to exploit an area in which there is still limited clinical data in support of stem cell therapy. Company relying on technology developed in North America and is signing up partnerships for manufacture of stem cells and their use in parts of the body. There has been some commentary recently on the relatively low valuations the market has given to stem cell companies and this will only change when clinical evidence becomes clear. Shares fell 32% in 2014 to company value of $21 million but there has been a 253% increase to $79 million in 2015 due to speculation on announcement that its manufacturing process for stem cells has been validated. The number of hurdles that Cynata will have to overcome indicates this recent jump is a short term spike. (11/3/15)
http://www.valutech.com.au/pages/pages/Biotech2015C.html